Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment
Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...
Nasdaq5d
Regeneron Announces Positive Phase 3 Results For EYLEA HD In Retinal Vein Occlusion Treatment
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...
GlobalData on MSN4d
Regeneron’s macular oedema therapy shows promise in Phase III trial
In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
modernretina3d
Regeneron reveals positive results from multiple trials evaluating Eylea HD (aflibercept) injection 8 mg
Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...
JD Supra6d
EU Biosimilar Regulatory and Launch Updates
CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars:  On January 30, 2025, the European Medicines Agency (EMA) Committee ...
Scientific Research Publishing11h
Frequency of Eye Diseases in Subjects Aged 40 and Over ()
Frequency of Eye Diseases in Subjects Aged 40 and Over. Open Journal of Ophthalmology, 15, 11-17. doi: ...
ophthalmologyadvisor6d
Susvimo Approval Expanded to Include Diabetic Macular Edema
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
Medscape1d
Hepatic Vein Thrombosis (Budd-Chiari Syndrome)
The antiphospholipid syndrome associated with hepatic vein thrombosis has usually been of the primary type; that is, the American Rheumatism Association criteria for the diagnosis of systemic ...